2024-Dec-20

Investor-Update QIV 2024

Milestones from the COVID-19 trial, Focus on rare diseases: DMD, Outlook 2025: Financing and further development, MetrioPharm AG Company Calendar 2025, MetrioPharm AG informs

more...

2024-Sep-26

Investor Relations News QIII 2024

Mode of Action of MetrioPharm's Lead Molecule MP1032, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs

more...

2024-Jun-28

Investor Relations News QII 2024

18th Annual General Meeting of MetrioPharm AG, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs

more...

2024-Mar-28

Investor Relations News QI 2024

Development Update from CSO Dr. Wolfgang Brysch, Company Calendar, MetrioPharm informs

more...

2023-Dec-19

Investor Relations News QIV 2023

Holiday Greetings from CEO Thomas Christély, MetrioPharm AG Company Calendar in H1 2024, MetrioPharm AG informs

more...

2023-Oct-04

Investor Relations News QIII 2023

Financing Round Continues, Development in Duchenne Muscular Dystrophy (DMD), MetrioPharm Company Calendar H2, MetrioPharm informs

more...

2023-Jul-04

Investor Relations News QII 2023

MetrioPharm AG has started a new financing round, 17th Annual General Meeting of MetrioPharm AG, Company Calendar, MetrioPharm informs

more...

2023-Mar-30

Investor Relations News QI 2023

Invitation to a Webinar, Company Calendar, MetrioPharm informs

more...

2022-Dec-22

Investor Relations News QIV 2022

more...

2022-Oct-12

Investor Relations News QIII 2022

MetrioPharm at BioPharm America in Boston, USA, Company Calendar in QIV 2022, MetrioPharm blog, MetrioPharm at Linkedin

more...